UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
15
April 2025 - Increase ownership of China JV to 100%
|
99.1
Haleon
plc: Increase ownership of China JV to
100%
15 April 2025:
Haleon plc (the "Company" or "Haleon") announces that following the
acquisition of a 33% equity interest in Tianjin TSKF Pharmaceutical
Co., Ltd. ("TSKF"), its OTC joint venture in China in December
2024, it has today entered into an agreement to acquire the
remaining 12% equity interest from its partner Tianjin
Pharmaceutical Da Ren Tang Group Corporation Limited ("DRTG"). This
transaction is for a total consideration of RMB 1,623 million (c.
£0.2 billion) and will result in TSKF becoming a wholly owned
subsidiary of Haleon.
The acquisition is expected to be funded through a combination of
Haleon's existing cash resources and new third-party
Renminbi-denominated debt. Subject to customary closing conditions,
including the approval of DRTG's shareholders and applicable
regulatory clearances, the transaction is expected to close within
the next three months.
Enquiries
|
Investors
|
Media
|
||
|
Jo Russell
|
+44 7787 392441
|
Zoë Bird
|
+44 7736 746167
|
|
Rakesh Patel
|
+44 7552 484646
|
Victoria Durman
|
+44 7894 505730
|
|
Emma White
|
+44 7823 523562
|
|
|
|
Email: [email protected]
|
Email: [email protected]
|
||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For more information please visit www.haleon.com
About TSKF
Founded in 1984, TSKF is a joint venture of Haleon, TPG and DRTG in
China. TSKF is a leading OTC company that manufactures and
distributes renowned products under Haleon's brands in China, such
as Fenbid, Contac, Bactroban, Voltaren and Flixonase in major
therapeutic areas such as Pain Relief, Respiratory Health and Skin
Health.
About DRTG
DRTG (SHSE: 600329 / SGX: T14) is the core pharmaceutical
manufacturing arm of TPG. DRTG is engaged in the research,
development and manufacturing of Chinese herbal medicines,
proprietary Chinese medicines, western medicine, and other products
primarily in China. The company is also involved in the wholesale
and retail of medicines in China. DRTG was founded in 1981 and
listed on the Singapore Stock Exchange and the Shanghai Stock
Exchange.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
April 15, 2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|